The Phase 2 clinical trial of exebacase (CF-301) from ContraFect Corp (NASDAQ:CFRX) are positive. According to the company, the treatment achieved meaningful clinical improvement in the primary efficacy endpoint at Day 14. Exebacase had a 70.4% responder rate, which was over and above the 60.0% responder rate achieved in patients who used antibiotics alone. Exebacase (CF-301) treats Staphylococcus aureus (Staph aureus), which causes bloodstream infections (BSIs) and it is commonly known as bacteremia.
From the results, there was a positive signal of efficacy, safety, and tolerability. The company’s Chairman and CEO Steven C. Gilman say that they are making great milestones. They can now progress to Phase 3 with all the confidence of being able to provide superior clinical responder rates.
The potential in Exebacase of being a first-in-class treatment for Staph aureus bacteremia
The trial engaged 121 patients from which 116 had confirmed Staph aureus bacteremia/endocarditis. Of all the patients, 71 received exebacase while 45 received placebo. The treatment events were adverse from the two groups. However, there were no reports of hypersensitivity, but at the end of the study, exebacase was reportedly safe and well-tolerated. Exebacase has the potential of being the solution to the treatment of Staph aureus bacteremia; thanks to its mechanism.
Meanwhile, ContraFec continues to strategize on how to aver the approximated 700,000 deaths, which occur yearly from antimicrobial-resistant infections. The company is committed and enthusiastic about the development of antibody products for life-threatening conditions.
Improvement of clinical outcomes for the serious and deadly infections
Staph aureus bacteremia is such a severe condition causing close to 200,000 hospitalizations in the United States. Its mortality rates range from 20-40%. Incidences of infective endocarditis have also increased notably on older, diabetic and hemodialysis patients. In the worst scenario, Staph aureus bacteremia causes infective endocarditis, which results into failed heart valves.
However, the Executive VP of Research and Development at ContraFect, Cara Cassino, says there is hope from the results. He explains, “These results represent the first step towards a potential new paradigm for treating life-threatening bacterial infections, improving patient outcomes, combating antimicrobial resistance and broadening our armamentarium against antibiotic-resistant pathogens.”